Document:

Exhibit 10.14

 

AMENDMENT #5 TO JOINT
DEVELOPMENT AGREEMENT

 

WHEREAS,
CDx, Inc. ("CDX") and Next Dimension Technologies, Inc. ("NDT") are parties to a Joint Development Agreement
executed by the parties on November 1, 2013, as modified by Amendment #1, Amendment #2, Amendment #3, and Amendment #4 to the
Joint Development Agreement executed by the parties on April 21, 2014, July 1, 2015, and March 13, 2015, and May 1, 2015, respectively
(the "Agreement"); and

 

WHEREAS, pursuant
to Paragraph 11.3 of the Agreement, both parties now desire to further modify and amend the Agreement;

 

NOW, THEREFORE,
in consideration of the mutual undertakings of the parties as set forth below as well as other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, CDX and NDT do hereby mutually agree as follows:

 

		1.	With respect to Exhibit A, Task 1.6, Task 1.6 shall be deleted in its entirety
and replaced with Exhibit A, Task 1.6 attached hereto.

 

		2.	With respect to Exhibit A, Task 3.1, Task 3.1 shall be deleted in its entirety
and replaced with Exhibit A, Task 3.1 attached hereto.

 

		3.	All remaining terms and conditions of Agreement remain in full force and effect, as modified
am. amended hereby and are hereby ratified by the parties.

 

		4.	After full execution of this Amendment #5, the Agreement shall be deemed to include the modifications and amendments herein.

 

IN WITNESS WHEREOF,
the parties have caused this Amendment #5 to be executed by their authorized representatives as of the respective dates written
below.

 

	CDX, Inc.	 	Next Dimension Technologies, Inc. 
	 	 	 	 	 
	By:	/s/ Daniel Yazbeck	 	By:	/s/ William Royea
	Name:	Daniel Yazbeck	 	Name:	William Royea
	Title:	President	 	Title:	President
	 	 	 	 	 
	Date:	May 5, 2015	 	Date:	May 5, 2015

    	1

    	 

    

Task
1.6: Development of reformulated sensor chemistries and a quantitative quality
control (QC) and calibration procedure for cannabis strain identification sensors

 

	Task
    objective	NDT
    will (1) evaluate the response of approximately 48 sensor element candidates against representative terpenes at various vapor
    concentrations, (2) reformulate sensor chemistries for cannabis strain matching applications to facilitate automated production,
    and (3) develop a procedure for quantitative calibration and quality control assessment of cannabis strain identification
    sensors for 16 key sensor elements to be selected by CDX no later than May 21, 2015.
	Key
    deliverables and deadlines	● Development
        of reformulated sensor chemistries for automated production (completed by May 5, 2015)

         

        ● Delivery
        of a presentation on the results of testing of candidate sensor elements against representative terpenes at various concentrations
        (completed by May 18, 2015)

         

        ● Development
        of a preliminary quality control protocol and delivery of one-hundred (100)                  
        (pre-calibrated and quality-control
        checked with a preliminary procedure) to CDX for further testing and data collection; sensors will be accompanied with
        recommended testing protocols (completed by June 5, 2015).

         

        ● Development
        of a refined quality control protocol that incorporates specific feedback received from CDX on or before May 15,
        2015. Delivery of 100 prototype sensor arrays (pre-calibrated and quality-control checked with refined procedure) to CDX
        for further testing and data collection (completed by June 12, 2015)

	Performance
    time	13
    weeks
	Anticipated
    start date	March
    16, 2015
	Anticipated
    completion date	June
    12, 2015
	Total
    budget	 
	Payment
    schedule	●
                      upon initiation of task (due by March 31,
        2015)

         

        ●               
        upon delivery of preliminary                    
        (due within 30 days of invoice)

         

        ●               
        upon delivery of refined                    
        (due within 30 days of invoice)

	Disclaimer	NDT
    will use reasonable efforts to achieve the performance goals and specifications set forth by CDX. Notwithstanding, the proposed
    work is developmental in nature, and thus NDT makes no representation and provides no guarantee that any performance goals
    or specifications set forth by CDX will be attained.

 

    	2

    	 

    

 

Task
3.1: Development of a prototype                      
for detection of pesticide and organic chemical residue on cannabis flower and on produce

 

	Task
    objective	NDT
    will develop a            for the detection of various pesticides and
    organic chemical residues on cannabis flower and on produce. This task will involve the fabrication, benchmarking, and
    testing of against 5-10 distinct pesticide residues and/or organic chemical vapors on 3 representative media (cannabis
    flower, a vegetable, and a fruit). Through the duration of the task, NDT will deliver prototype samples of the sensor arrays
    (along with recommended testing protocols) to CDX for testing and evaluation.
	Key
    deliverables and deadlines	●
                                                                                                                                                                           Design, fabrication and benchmarking of initial              and
                                                                                                                                                                           preliminary testing against pesticides and organic chemical residues (completed by May 29, 2015)

         

        ●
        Delivery of one-hundred (100) initial prototype             
        and recommended testing protocols to a delivery address to be provided by CDX (shipped by May 29, 2015)

         

        ●
        Design, fabrication, and benchmarking of reformulated             
        and testing against pesticides and organic chemical residues both ex situ and on representative media (completed
        by July 31, 2015)

         

        ●
        Delivery of one-hundred (100) reformulated prototype             
        and recommended testing protocols to a delivery address to be provided by CDX (shipped by July 31, 2015)

         

        ●
        Design, fabrication, and benchmarking of optimized             
        and testing against pesticides and organic chemical residues both ex situ and on representative media (completed
        by September 25, 2015)

         

        ●
        Delivery of one-hundred (100) optimized prototype             
        and recommended testing protocols to a delivery address to be provided by CDX (shipped by September 25, 2015)

	Performance
    time	31
    weeks
	Anticipated
    start date	March
    1, 2015
	Anticipated
    completion date	September
    25, 2015
	Total
    budget	$
	Payment
    schedule	●
                      upon initiation of task (due by March 31,
        2015)

         

        ●
                      upon
shipment of reformulated prototype             July 31, 2015 (due within
30 days of invoice)

         

        ●
                      upon
        shipment of optimized prototype             September 25, 2015
        (due within 30 days of invoice)

	Disclaimer	NDT
    will use reasonable efforts to achieve the performance goals and specifications set forth by CDX. Notwithstanding, the proposed
    work is developmental in nature, and thus NDT makes no representation and provides no guarantee that any performance goals
    or specifications set forth by CDX will be attained.

 

 

3EXHIBIT  10.42

 

STOCK OPTION AGREEMENT

 

This Stock Option Agreement
(“Agreement”) is between Cryoport, Inc. (“Company”) and Jerrell Shelton (the “Optionee”),
and is effective as of December 18, 2014 (“Grant Date”).

 

AGREEMENT

 

In consideration of
the mutual covenants and conditions hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Optionee agree as follows:

 

1. Grant of
Option. Subject to the terms of this Agreement, the Company grants to the Optionee the right and option to purchase from
the Company all or any part of an aggregate of 3,150,000 shares of the Common Stock of the Company (“Option”).
The Option granted under this Agreement is not intended to be an “incentive stock option” under Section 422
of the Internal Revenue Code of 1986, as amended (the “Code”).

 

2. Purchase
Price. The purchase price under this Agreement is $0.40, the per share closing price the of Common Stock of the
Company (“Stock”) on the Grant Date, which is equal to the fair market value of a share of Stock on the Grant Date.

 

3. Vesting
of Option. The Option shall vest and be exercisable according to the following schedule:

 

1/48 of the options vest on
the 18th of each month for forty eight months beginning on 1/18/2015 and ending on 12/18/2019

 

Provided that such vesting will be accelerated on the date that
the Company files a Form 10-Q or Form 10-K indicating an income from operations for the Company in two consecutive fiscal quarters;

 

Provided further, that, pursuant to Section 13 below, such vesting
will be accelerated in the event of a Change of Control (as defined in Section 13).

 

4. Exercise
of Option. This Option may be exercised, to the extent vested (under Section 3 above), in whole or in part at any time
before the Option expires by delivery of a written notice of exercise (under Section 6 below) and payment of the purchase price
in cash or such other method permitted by the Compensation Committee of the Board of Directors of the Company (the “Committee”)
under Section 5 and communicated to the Optionee before the date the Optionee exercises the Option.

 

5. Payment.
The Committee may determine methods other than cash by which the exercise price of the Option may be paid, the form of payment,
including, without limitation, cash, promissory note, shares of Stock held for longer than six months (through actual tender or
by attestation), any net-issuance arrangement or other property acceptable to the Committee (including broker-assisted “cashless
exercise” arrangements), and the methods by which shares of Stock shall be delivered or deemed to be delivered to the Optionee.

 

    	 

    	 

    

 

6. Method
of Exercising Option. Subject to the terms of this Agreement, the Option may be exercised by timely delivery to the Company
of written notice, which notice shall be effective on the date received by the Company. The notice shall state the Optionee’s
election to exercise the Option and the number of underlying shares in respect of which an election to exercise has been made.
Such notice shall be signed by the Optionee, or if the Option is exercised by a person or persons other than the Optionee because
of the Optionee’s death, such notice must be signed by such other person or persons and shall be accompanied by proof acceptable
to the Company of the legal right of such person or persons to exercise the Option.

 

7. Registration.
The Company shall use its commercially reasonable efforts to file a registration statement on Form S-3 under the Securities Act
of 1933, as amended, covering the resale of the Stock and will use its commercially reasonable efforts to cause such registration
statement to be declared effective as soon as practicable.

 

8. Term of
Option. The Option granted under this Agreement expires at the earlier of (a) ten (10) years from the Grant Date, through
and including the normal close of business of the Company on the tenth (10th) anniversary of the Grant Date, and (b)
ninety (90) days after the resignation and/or removal of the Optionee as an employee of the Company, through and including the
normal close of business of the Company on the ninetieth (90th) day after such resignation and/or removal.

 

9. Tax Withholding.
Unless otherwise provided by the Committee prior to the vesting of Option, the Optionee shall satisfy any federal, state, local
or foreign employment or income taxes due upon the vesting of Option (or otherwise) by having the Company withhold from those shares
of Stock that the Optionee would otherwise be entitled to receive, a number of shares having a fair market value equal to the minimum
statutory amount necessary to satisfy the Company’s applicable federal, state, local and foreign income and employment tax
withholding obligations. Any such withholding shall be subject to the provisions of applicable law and to any conditions the Committee
may determine to be necessary to comply with Rule 16b-3 or its successors under the Exchange Act. In lieu of, and subject
to, the above, the Committee may also permit the Optionee to satisfy any federal, state, local, or foreign employment or income
taxes due upon the vesting of Option (or otherwise) by (i) personal check or other cash equivalent acceptable to the Company,
(ii) permitting the Optionee to execute a same day sale of Stock pursuant to procedures approved by the Company, or (iii) such
other method as approved by the Committee, all in accordance with applicable Company policies and procedures and applicable law.

 

10. Nontransferability.
The Option granted by this Agreement shall not be transferable by the Optionee or any other person claiming through the Optionee,
either voluntarily or involuntarily, except by will or the laws of descent and distribution.

 

11. Nonstatutory
Stock Option. The Option granted hereunder is a nonstatutory (non-qualified) stock option, and is not an “incentive
stock option” pursuant to the Code.

 

    	2

    	 

    

 

12. Stock
Certificates. Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any
certificates evidencing shares of Stock pursuant to the exercise of the Option, unless and until the Committee has determined,
with advice of counsel, that the issuance and delivery of such certificates is in compliance with all applicable laws, regulations
of governmental authorities and, if applicable, the requirements of any exchange or quotation system on which the shares of Stock
are listed, quoted or traded. All Stock certificates delivered pursuant to this Agreement are subject to any stop-transfer orders
and other restrictions as the Committee deems necessary or advisable to comply with Federal, state, or foreign jurisdiction, securities
or other laws, rules and regulations and the rules of any national securities exchange or automated quotation system on which the
Stock is listed, quoted, or traded. The Committee may place legends on any Stock certificate to reference restrictions applicable
to the Stock. In addition to the terms and conditions provided herein, the Board Directors may require that the Optionee make such
reasonable covenants, agreements, and representations as the Board of Directors, in its discretion, deems advisable in order to
comply with any such laws, regulations, or requirements.

 

13. Change
in Control. Notwithstanding any other provision herein to the contrary, upon a Change in Control, the entire Option shall
automatically become immediately vested and/or exercisable and that all restrictions relating to the Option shall lapse.

 

a. “Change
in Control” means any one or more of the following events:

 

(i) The date that
any one person, or more than one person acting as a group (as determined in accordance with Treasury Regulation Section 1.409A-3(i)(5)),
acquires ownership of stock of the Company that, together with stock held by such person or group, constitutes more than 50% of
the total fair market value or total voting power of the stock of the Company. This paragraph (i) only applies when there
is a transfer of stock of the Company (or issuance of stock of the Company) and stock in the Company remains outstanding after
the transaction;

 

(ii) The date that
any one person, or more than one person acting as a group (as determined in accordance with Treasury Regulation Section 1.409A-3(i)(5)),
acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons)
assets from the Company that have a total gross fair market value equal to or more than 40% of the total gross fair market value
of all of the assets of the Company immediately prior to such acquisition or acquisitions. For this purpose, “gross fair
market value” means the value of the assets of the Company, or the value of the assets being disposed of, determined without
regard to any liabilities associated with such assets; or

 

(iii) The date that
any person, or more than one person acting as a group (as determined in accordance with Treasury Regulation 1.409A-3(i)(5)),
acquires (or has acquired during the 12-month period ending on the most recent acquisition by such person or persons) ownership
of stock of Company possessing 30% or more of the total voting power of the stock of Company.

 

    	3

    	 

    

 

The transfer of stock
or assets of the Company in connection with a bankruptcy filing by or against the Company under Title 11 of the United States Code
will not be considered to be a Change of Control for purposes of this Agreement. Additionally, a transaction shall not constitute
a Change in Control if its sole purpose is to change the state of the Company’s incorporation or to create a holding company
that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before
such transaction.

 

14. Waiver
and Modification. The provisions of this Agreement may not be waived or modified unless such waiver or modification is
in writing and signed by a representative of the Committee.

 

15. Adjustments.
In the event of any change in the outstanding shares of Stock by reason of a stock dividend or split, recapitalization, merger,
consolidation, combination, exchange of shares, or other similar corporate change, the aggregate number of shares of Stock subject
to the Option and its stated exercise price shall be adjusted appropriately by the Committee, whose determination shall be conclusive;
provided, however, that fractional shares shall be rounded to the nearest whole share. Moreover, in the event of such transaction
or event, the Committee, in its discretion, may provide in substitution for the Option such alternative consideration (including
cash) as it, in good faith, may determine to be equitable under the circumstances and may require in connection therewith the surrender
of the Option so replaced. Further, with respect to any Option that otherwise satisfies the requirements of the stock rights exception
to Section 409A of the Code, any adjustment pursuant to this Section 15 shall be made consistent with the requirements
of the final regulations promulgated pursuant to Section 409A of the Code.

 

16. Requirements
of Law

 

a. Securities
Act. The Company shall not be required to deliver any shares of Stock pursuant to the vesting of the Option if, in the
opinion of counsel for the Company, such issuance would violate the Securities Act of 1933 or any other applicable federal or state
securities laws or regulations. The granting of the Option and the issuance of shares and/or cash under this Agreement shall
be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities
exchanges as may be required. The Company shall be under no obligation to register pursuant to the Securities Act of 1933, as amended,
any of the shares of Stock paid pursuant to the Agreement. If the shares of Stock paid pursuant to the Agreement may in certain
circumstances be exempt from registration pursuant to the Securities Act of 1933, as amended, the Company may restrict the transfer
of such shares in such manner as it deems advisable to ensure the availability of any such exemption.

 

b. Securities
Law Compliance. If Optionee is obligated to file reports pursuant to Section 16 of the Exchange Act, transactions
pursuant to this Agreement are intended to comply with all applicable conditions of Rule 16b-3 or its successors pursuant
to the Securities Exchange Act of 1934. Notwithstanding any other provision herein, the Committee may impose such conditions on
the exercise of the Option as may be required to satisfy the requirements of Rule 16b-3 or its successors pursuant to the Securities
Exchange Act of 1934. To the extent any provision herein or action by the Committee fails to so comply, it shall be void to the
extent permitted by law and voidable as deemed advisable by the Committee.

 

    	4

    	 

    

 

c. Restrictions.
The Committee shall impose such restrictions on the Option as it may deem advisable, including without limitation, restrictions
under applicable federal securities law, under the requirements of any Stock exchange upon which the Stock is then listed and under
any blue sky or state securities laws applicable to such Option.

 

17. Section 409A of the Code.

 

a. General Compliance.
If this Agreement is subject to Section 409A of the Code, the Company intends (but cannot and does not guarantee) that this
Agreement complies fully with and meets all of the requirements of Section 409A of the Code or an exception thereto. To the
extent necessary to comply with Section 409A of the Code, this Agreement may be modified, replaced or terminated in the discretion
of the Committee. Notwithstanding any provision of this Agreement to the contrary, in the event that the Committee determines that
this Agreement is or may become subject to Section 409A of the Code, the Company may adopt such amendments to this Agreement,
without the consent of Optionee, or adopt other policies and procedures (including amendments, policies and procedures with retroactive
effective dates), or take any other action that the Committee determines to be necessary or appropriate to either comply with Section
409A of the Code or to exclude or exempt this Agreement from the requirements of Section 409A of the Code.

 

b. Delay for
Specified Employees. If, at the time of Optionee’s “separation of service” the Company has any Stock
which is publicly traded on an established securities market or otherwise, and if the Optionee is considered to be a “specified
employee” to the extent any payment or consideration under this Agreement is subject to the requirements of Section 409A
of the Code and is payable upon the Optionee’s “separation from service,” such payment shall not commence prior
to the first business day following the date which is six (6) months after the Optionee’s “separation from service”
(or if earlier than the end of the six (6) month period, the date of the Optionee’s death). Any amounts that would have
been distributed during such six (6) month period will be distributed on the day following the expiration of the six (6) month
period.

 

c. Prohibition
on Acceleration or Deferral. Under no circumstances may the time or schedule of any payment for any amount under this Agreement
that is subject to the requirements of Section 409A of the Code be accelerated or subject to further deferral except as otherwise
permitted or required pursuant to regulations and other guidance issued pursuant to Section 409A of the Code. If the Company
fails to make any payment pursuant to the payment provisions applicable to this Agreement that is subject to Section 409A
of the Code, either intentionally or unintentionally, within the time period specified in such provisions, but the payment is made
within the same calendar year, such payment will be treated as made within the time period specified in the provisions. In addition,
in the event of a dispute with respect to any payment, such payment may be delayed in accordance with the regulations and other
guidance issued pursuant to Section 409A of the Code.

 

    	5

    	 

    

 

18. Voting
and Other Shareholder Related Rights. The Optionee will have no voting rights or any other rights as a shareholder of the
Company with respect to any Option until exercised by the Optionee.

 

19. Governing
Law. This Agreement shall be interpreted and administered under the laws of the State of Nevada.

 

20. Amendments.
This Agreement may be amended only by a written agreement executed by the Company and the Optionee.

 

IN WITNESS WHEREOF,
the Company has caused this Agreement to be executed by its duly authorized representative and Optionee has signed this Agreement,
and this Agreement shall be effective as of the day and year first written above.

 

	 	 	 	 
	 	 	Cryoport, Inc. 
	 	 	 	 
	12/18/14	 	By:	 
	Date	 	Name:  	Robert Stefanovich
	 	 	Title:	Chief Financial Officer

  

    	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]